Tango Therapeutics

NMQ:TNGX · US87583X1090

BiotechnologySmall

360

Value43

Profit price86

Cash yield1

Sales & asset price8

Price/Sales8

Price/Book7

Quality31

Returns on capital39

Return on Capital38

Cash Return on Capital45

Return on Equity35

Profit margins15

EBIT Margin5

Gross Profitability24

Cash backing23

Accruals19

Owner Earnings Margin26

Growth43

Sales growth1

Profit growth29

Reinvestment58

Price momentum98

Safety35

Debt load49

Debt serviceability44

Refinancing87

Debt Payback1

Liquidity21

Sentiment58

Analyst ratings23

Expectations trend29

Opinion Changes26

Price Target Upside32

Market mood81

Value Creation8/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Tango Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Employees149

Websitetangotx.com

ISINUS87583X1090

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

GeneticsPulmonologyImmunologyCentral Nervous SystemOncologyChronic DiseasesBiotechnologyHealth CareMedicalTherapeutics

Description

Tango Therapeutics, Inc. (Tango Therapeutics) leverages its state-of-the-art target discovery platform to identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need.…

Analysis

Weak and unloved

Tango Therapeutics, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 8/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Tango Therapeutics with its peers

Pyxis Oncology

NSQ:PYXS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Greenwich Lifesciences

NAQ:GLSI

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tyra Biosciences

NSQ:TYRA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tenaya Therapeutics

NSQ:TNYA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Black Diamond Therapeutics

NSQ:BDTX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Larimar Therapeutics

NMQ:LRMR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →